Mycophenolate
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Take orally twice daily (morning and evening), approximately 12 hours apart on an empty stomach (1 hour before or 2 hours after meals) with water. Swallow whole; do NOT crush, chew, or divide. Note: 360 mg of mycophenolate sodium delivers equimolar MPA to 500 mg of mycophenolate mofetil.
⚠️ Side Effects
Common: Diarrhea, nausea, vomiting, abdominal pain, leukopenia, anemia, thrombocytopenia, infection. Rare/Severe: Severe opportunistic infections (CMV viremia, BK virus nephropathy), Progressive Multifocal Leukoencephalopathy (PML), and pure red cell aplasia (PRCA).
🛡️ Safety Warnings
Black Box Warning: First-trimester pregnancy loss and congenital malformations (severe embryofetal toxicity); female patients must use two reliable forms of contraception and complete negative pregnancy tests. Black Box Warning: Increased risk of opportunistic infections and lymphomas. Black Box Warning: Pure red cell aplasia. Space antacids and sevelamer at least 2 hours apart.
Jan Aushadhi Products containing Mycophenolate
Found 2 generic formulation(s) containing this active ingredient.
Mycophenolate Mofetil Tablets 500mg
Mycophenolate Mofetil Tablets (500mg) and Mycophenolate Sodium Gastro-Resistant Tablets (360mg) is an oral prodrug of mycophenolic acid (MPA) on the WHO Model List of Essential Medicines. MPA is a potent, selective, non-competitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de novo guanine nucleotide synthesis. Because T- and B-lymphocytes rely almost exclusively on the de novo pathway for purine generation (unlike other cell types that utilize the salvage pathway), mycophenolate selectively blocks lymphocyte proliferation and antibody production. Indicated in combination with cyclosporine/tacrolimus and corticosteroids for prophylaxis of organ rejection in kidney, heart, and liver allografts, and for induction and maintenance of lupus nephritis.
Mycophenolate Sodium Gastro-resistant Tablets 360mg
Mycophenolate Mofetil Tablets (500mg) and Mycophenolate Sodium Gastro-Resistant Tablets (360mg) is an oral prodrug of mycophenolic acid (MPA) on the WHO Model List of Essential Medicines. MPA is a potent, selective, non-competitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de novo guanine nucleotide synthesis. Because T- and B-lymphocytes rely almost exclusively on the de novo pathway for purine generation (unlike other cell types that utilize the salvage pathway), mycophenolate selectively blocks lymphocyte proliferation and antibody production. Indicated in combination with cyclosporine/tacrolimus and corticosteroids for prophylaxis of organ rejection in kidney, heart, and liver allografts, and for induction and maintenance of lupus nephritis.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Mycophenolate.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Mycophenolate Mofetil Tablets 500mg | 10's | ₹180.00 | cellCEPT | ₹728.00 | 75% Save |
| Mycophenolate Sodium Gastro-resistant Tablets 360mg | 10's | ₹145.00 | MYFORTIC, MMF, IMMUTIL, MANOCEPT | ₹825.71 | 82% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Mycophenolate generics.